What is Inscopix?
Inscopix operates as a critical enabler in the biotechnology sector, providing sophisticated tools for the real-time visualization of neural activity. The company's core value proposition lies in its ability to move beyond traditional behavioral assays, offering quantitative, objective data that significantly improves the predictive accuracy of therapeutic candidates for complex brain disorders. By decoding the brain's intricate mechanisms, Inscopix empowers pharmaceutical partners to screen drugs with higher precision, effectively reducing the failure rates associated with neuro-therapeutic development. This market position is bolstered by a commitment to innovation, transforming how researchers understand disease mechanisms and therapeutic intervention.
How much funding has Inscopix raised?
Inscopix has raised a total of $11M across 2 funding rounds:
Series A
$10M
Debt
$1M
Series A (2016): $10M with participation from Floodgate Fund, Playground, and AME Cloud Ventures
Debt (2020): $1M led by PPP
Key Investors in Inscopix
Floodgate Fund
Floodgate Fund is a venture capital firm that specializes in early stage investments in technology companies, focusing on pattern-breaking founders.
Playground
Playground Global invests in founders harnessing frontier technologies, including life sciences and artificial intelligence, to build transformational businesses.
AME Cloud Ventures
AME Cloud Ventures focuses on seed to later stage companies that build infrastructure and value chains around data, supporting technology-heavy enterprises.
What's next for Inscopix?
With the recent influx of capital, Inscopix is well-positioned to accelerate its strategic roadmap, focusing on the expansion of its neuro-assay platform and the deepening of its partner ecosystem. The company is expected to leverage this financing to enhance its predictive modeling capabilities, further cementing its role as an essential partner for global pharmaceutical firms. As the industry shifts toward data-driven drug discovery, Inscopix's focus on actionable neural insights will likely drive long-term growth, potentially leading to new therapeutic breakthroughs in previously intractable neurological conditions. The firm remains a key player to watch as it scales its infrastructure to meet the rising demand for high-fidelity brain circuit analysis.
See full Inscopix company page
